AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26341218
Drug: SUPER algorithm
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUPER algorithm for early administration of analgesic drugs
Trial: 26341218
Drug: Normal process
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal process of access to pain-control drugs (Group A)
Trial: 20806117
Drug: Apixaban 10
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 10 mg twice daily
Trial: 23451769
Drug: Apixaban 25
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 25 mg twice daily
Trial: 23451769
Drug: Apixaban 25
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 25 mg once daily
Trial: 22184801
Drug: Micronutrient combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient combination (vitamins C and D3, folic acid, and selenium)
Trial: 20578847
Drug: 3-day per
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day per week take-home dosing schedule
Trial: 20578847
Drug: 3-day per
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day per week clinic dosing schedule
Trial: 20578847
Drug: Daily dosing
RxNorm normalized name: Osmolex 322 MG Daily Dosing Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing schedule
Trial: 20578847
Drug: 3-day per
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day per week supervised dosing
Trial: 9252908
Drug: Cisapride, 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride, 0.2 mg/kg three times daily
Trial: 8296578
Drug: Tricyclic antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressants (imipramine, clomipramine, desipramine)
Trial: 3520319
Drug: Intravenous ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin during labor
Trial: 25753932
Drug: Telephone-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered cognitive behavioral treatment (CBT) for high anxiety sensitivity, delivered over eight weeks.
Trial: 24184053
Drug: PST (periosteal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PST (periosteal stimulation therapy) once a week for 10 weeks followed by PST boosters for 6 months
Trial: 18787510
Drug: IV PTX
RxNorm normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PTX 500 mg bolus followed by IV infusion of PTX 700 mg for two hours
Trial: 15192991
Drug: ROI measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROI measurement in physical therapy clinical program
Trial: 9284714
Drug: SRIH infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRIH infusion (90‐min iv infusion of SRIH at a rate of 9 micrograms/kg.h)
Trial: 9284714
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (90‐min iv infusion of isovolumetric amounts of 0.9% saline)
Trial: 9284714
Drug: SRIH infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRIH infusion
Trial: 3532693
Drug: Fractionated diazoxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated diazoxide administered intravenously (n = 28)
Trial: 3532693
Drug: Dihydralazine administered
RxNorm normalized name: dihydralazine
DrugBank: Dihydralazine (DB12945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine administered intramuscularly (n = 24)
Trial: 3532693
Drug: Both drug
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drug regimens (diazoxide and dihydralazine)
Trial: 3532693
Drug: Furosemide administered
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide administered intravenously (40 mg)
Trial: 29441952
Drug: O/V ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O/V ointment with 2% silver fir bark extract
Trial: 27646425
Drug: Baseline CRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline CRP levels ≤ 3.0mg/L
Trial: 27646425
Drug: Moderately/markedly elevated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately/markedly elevated CRP levels (≥6.9mg/L; 24% of patients)
Trial: 24676963
Drug: Maintenance cognitive
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance cognitive stimulation therapy (CST) weekly group programme for 24 weeks
Trial: 24676963
Drug: Maintenance cognitive
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance cognitive stimulation therapy (CST) weekly group programme for 24 weeks (subgroup taking AChEIs)
Trial: 22627378
Drug: Ductal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ductal Injection (DI) with Serva collagenase
Trial: 22627378
Drug: Ductal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ductal Injection (DI) with Liberase MTF
Trial: 22627378
Drug: No Ductal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Ductal Injection (no DI)
Trial: 19915202
Drug: EPA (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA (1.6 g/day) and DHA (1.2 g/day)
Trial: 19915202
Drug: Mineral oil
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral oil (2.4 ml/day)
Trial: 18076918
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of epirubicin plus oral administration of Lactobacillus casei preparation (3 gm per day for 1 year)
Trial: 18076918
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of epirubicin (30 mg/30 ml saline twice during 1 week, plus 6 additional instillations during 3 months)
Trial: 3283624
Drug: MP induction
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP induction treatment every 6 months
Trial: 3283624
Drug: VCMP induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCMP induction treatment every 6 months
Trial: 3283624
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment using the induction scheme Q 8 weeks
Trial: 3283624
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further chemotherapy after remission induction
Trial: 30937935
Drug: Dose-adjusted warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted warfarin (INR: 2.0-3.0)
Trial: 11194089
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg) plus placebo
Trial: 11194089
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg) plus placebo
Trial: 27060151
Drug: Bortezomib-dexamethasone therapy
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib-dexamethasone therapy
Trial: 18671197
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of Ageratina pichinchensis extract (phytopharmaceutical formulation in lacquer solution) for 6 months
Trial: 18671197
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with 8% ciclopirox lacquer solution for 6 months
Trial: 16860051
Drug: 6% cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% cellulose sulfate gel, 3.5 ml, vaginally, bid, for 14 days
Trial: 16860051
Drug: K-Y Jelly,
RxNorm normalized name: K-Y Jelly, topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-Y Jelly, 3.5 ml, vaginally, bid, for 14 days
Trial: 16860051
Drug: 6% cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% cellulose sulfate gel and K-Y Jelly
Trial: 8853755
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg morning dosing
Trial: 8853755
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg evening dosing
Trial: 1735345
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg three times a day for 30 days)
Trial: 6715083
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg metildigoxin (Lanitop)
Trial: 6715083
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg beta‐acetyldigoxin (Novodigal)
Trial: 24521088
Drug: Alters who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alters who did not use drugs
Trial: 20657257
Drug: BBS (antibiotic-impregnated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBS (antibiotic-impregnated bioabsorbable bone substitute)
Trial: 20657257
Drug: PMMA (antibiotic-impregnated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMMA (antibiotic-impregnated polymethylmethacrylate cement beads)
Trial: 17482880
Drug: Escalated-dose CFRT
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated-dose CFRT
Trial: 17482880
Drug: Standard-dose CFRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose CFRT
Trial: 12085202
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy followed by tamoxifen
Trial: 12085202
Drug: Standard-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose chemotherapy followed by tamoxifen
Trial: 26549586
Drug: Intravenous PEG-asparaginase
RxNorm normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous PEG-asparaginase (15 doses of 2500 IU/m² every 2 weeks)
Trial: 26549586
Drug: Intramuscular native
RxNorm normalized name: Castanea sative leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular native E coli L-asparaginase (30 doses of 25,000 IU/m² weekly)
Trial: 26549586
Drug: Intravenous PEG-asparaginase
RxNorm normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous PEG-asparaginase
Trial: 26549586
Drug: Intramuscular native
RxNorm normalized name: Castanea sative leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular native E coli L-asparaginase
Trial: 20733274
Drug: Oxandrolone (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (0.06 mg/kg/day) with Growth Hormone (GH 0.35 mg/kg/week)
Trial: 20733274
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH 0.35 mg/kg/week) with Placebo (Pl)
Trial: 19339393
Drug: Diet of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet of 5 servings of vegetables and fruit daily (Control)
Trial: 12818944
Drug: Subarachnoid isobaric
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subarachnoid isobaric lidocaine 30 mg
Trial: 12818944
Drug: Subarachnoid hyperbaric
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subarachnoid hyperbaric bupivacaine 5.25 mg
Trial: 10890135
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg mefloquine administered on days 0, 1, 7, 14, 21 and 28; further 5 weekly doses of 250 mg mefloquine.
Trial: 10890135
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg mefloquine administered as further 5 weekly doses.
Trial: 8851688
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg po at -60 min)
Trial: 8851688
Drug: Salbutamol (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.08 mg/kg po at -60 min)
Trial: 1635441
Drug: Bronchodilator
RxNorm normalized name: Bronchodilator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator
Trial: 6369532
Drug: Cefazolin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (0.5 g every 6 h for 4 days)
Trial: 6369532
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 g every 12 h for 2 days)
Trial: 26137975
Drug: Atacicept (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept (150 mg subcutaneous injections once weekly for 25 weeks)
Trial: 18975334
Drug: Alendronate (ALN)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN) 5 mg orally, once daily
Trial: 18975334
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antiresorptive treatment)
Trial: 16871061
Drug: Videotape-assisted oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videotape-assisted oral feedback
Trial: 11783101
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (CDDP)
Trial: 9365765
Drug: Other drug
RxNorm normalized name: Other drugs for bile therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drug regimens (albendazole plus metronidazole, sulphadiazine plus pyrimethamine, atovaquone, doxycycline plus nifuroxazide, itraconazole, flubendazole, chloroquine, paromomycin, sparfloxacin)
Trial: 3305212
Drug: Sustained chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained chemotherapy
Trial: 3305212
Drug: Multi-centre therapy
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-centre therapy
Trial: 25175842
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine (100 mg)
Trial: 25175842
Drug: Topical ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ropivacaine (37.5 mg)
Trial: 23050696
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus (Lac) at 2 g/kg diet
Trial: 23050696
Drug: Hydrated sodium
RxNorm normalized name: Hydrated sodium borate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrated sodium calcium aluminosilicate (HSCAS) at 2 g/kg diet
Trial: 23050696
Drug: Mannan oligosaccharides
RxNorm normalized name: Konjac mannan
DrugBank: Konjac mannan (DB14963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannan oligosaccharides (MOS) at 2 g/kg diet
Trial: 16547085
Drug: Protocol A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A: 2 g/kg/day of protein equivalent
Trial: 16547085
Drug: Protocol B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B: 1.2 g/kg/day protein equivalent
Trial: 12535038
Drug: 15 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg.kg‐1 magnesium in 30 ml 0.9% NaCl over 20 min
Trial: 3552020
Drug: Hydroxychloroquine (HC)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HC) 400 mg daily for the first month, then 200 mg daily thereafter
Trial: 28960254
Drug: JTE-052 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTE-052 ointment at 0.25%
Trial: 28960254
Drug: JTE-052 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTE-052 ointment at 0.5%
Trial: 28960254
Drug: JTE-052 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTE-052 ointment at 1%
Trial: 28960254
Drug: JTE-052 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTE-052 ointment at 3%
Trial: 29071930
Drug: Long-snake moxibustion
RxNorm normalized name: North American coral snake antivenin
DrugBank: Coral snake (micrurus fulvius) immune globulin antivenin (equine) (DB13883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-snake moxibustion treatment
Trial: 29071930
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine (Yupingfeng Granules)
Trial: 29071930
Drug: Moxibustion vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion vs Herbal medicine
Trial: 12242598
Drug: Venoruton powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoruton powder 0.5 g
Trial: 12242598
Drug: Venoruton powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoruton powder 1 g
Trial: 12242598
Drug: Venoruton powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoruton powder 2 g
Trial: 12242598
Drug: Venoruton powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoruton powder 4 g
Trial: 12242598
Drug: Venoruton powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoruton powder (all doses)
Trial: 7652030
Drug: Nicotine dose
RxNorm normalized name: nicotine Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine dose (15 micrograms/kg, approx. 1.1 mg for average subject)
Trial: 2761122
Drug: NaHCO3 (E)
RxNorm normalized name: NaHCO3
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NaHCO3 (E) 0.2 g.kg‐1 body wt
Trial: 326642
Drug: Loperamide (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (6 mg daily)
Trial: 7790550
Drug: Injection flow:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection flow: 4 ml/s (Protocol 3)
Trial: 7790550
Drug: Injection flow:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection flow: 4 ml/s (60 ml) + 2 ml/s (40 ml) (Protocol 2)
Trial: 7790550
Drug: Injection flow:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection flow: 2 ml/s (Protocol 1)
Trial: 387496
Drug: Choline theophyllinate
RxNorm normalized name: Choline theophyllinate
DrugBank: Oxtriphylline (DB01303)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Choline theophyllinate 400 mg
Trial: 26313620
Drug: One Session
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Session Treatment (OST) with e-therapy homework maintenance program over 4 weeks
Trial: 23358514
Drug: CTD0.02 (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTD0.02 (0.02 mg CTD/kg body weight)
Trial: 23358514
Drug: CTD1 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTD1 (1 mg CTD/kg body weight)
Trial: 23358514
Drug: CTD50 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTD50 (50 mg CTD/kg body weight)
Trial: 23358514
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg CTD/kg body weight)
Trial: 16923699
Drug: Nebulized pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized pentoxifylline (PTXF) 20 mg/kg (spontaneous breathing) or 10 mg/kg (ventilatory support) every 6 hours for 3 days
Trial: 16923699
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (DX) 0.25 mg/kg every 12 hours for 3 days
Trial: 15059684
Drug: 4 units
RxNorm normalized name: Afrezza, 4 units inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 units of alcohol (4 UA: 32 g ethyl alcohol, 1203.8 kJ)
Trial: 15059684
Drug: 1 unit
RxNorm normalized name: Autopen Cartridge 1 unit, 3 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 unit of alcohol (1 UA: 8 g ethyl alcohol, 498.2 kJ)
Trial: 8167351
Drug: Busulfan (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulfan (16 mg/kg, n = 88)
Trial: 25790835
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) injections at postoperative days 7 and 14
Trial: 20420283
Drug: Dinoprostone vaginal
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone vaginal insert (10 mg for 12 hours)
Trial: 20420283
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (20 IU during cesarean delivery)
Trial: 16803851
Drug: Bromocriptine (D2R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (D2R agonist)
Trial: 10637064
Drug: Intraperitoneal cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal cisplatin (50 mg/m²) plus intravenous epidoxorubicin (60 mg/m²) and intravenous cyclophosphamide (600 mg/m²)